Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VT-122 in Progressive Prostate Cancer
NCT01857817Phase 2Terminated
- Sponsor
- Vicus Therapeutics
- Start
- Jun 2013
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in prostate cancer (PCa) comparing VT-122 with Placebo (2 arms). Primary endpoint: Change in prostate specific antigen at 12 weeks. Started Jun 2013; status: terminated.
02
Drugs
propranolol + etodolac
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT01857817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01857817.